FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pharmaceutical composition and method of treating cognitive disorders. Pharmaceutical composition contains pharmaceutically effective cholinesterase inhibitor, selected from physostigmine and galantamine, and compound of formula I. Method of treating cognitive disorders involves introduction to patient pharmaceutical composition, containing cholinesterase inhibitor, selected from physostigmine and galantamine, and compound of formula I.
EFFECT: invention implementation provides effective treatment of cognitive disorders with insignificant side effects.
9 cl, 2 ex, 5 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING VORTIOXETINE AND DONEPEZIL | 2013 |
|
RU2635528C2 |
| METHYLTHIONINIUM AS COGNITIVE ENHANCER | 2020 |
|
RU2824584C2 |
| APPLICATION OF CARBAMAZEPINE DERIVATIVES FOR TREATING EXCITATION IN PATIENTS SUFFERING FROM DEMENTIA | 2004 |
|
RU2351338C2 |
| THERAPEUTIC INTERACTIONS OF LEUKOMETHYLTHIONINIUM | 2020 |
|
RU2834773C2 |
| APPLICATION OF CHOLINESTERASE INHIBITORS FOR TREATMENT OF VASCULAR DEPRESSION | 2005 |
|
RU2397762C2 |
| COMBINED MEDICATION FOR WEIGHT-REDUCING TREATMENT | 2004 |
|
RU2363458C2 |
| ACTIVE INGREDIENT OF MEDICINAL AGENT, MEDICINAL AGENT, PHARMACEUTICAL CONPOSITION AND METHOD OF DEMENT SYNDROME TREATMENT | 2007 |
|
RU2327480C1 |
| DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
| COMPOSITION WHICH CONTAINS VIRUS-LIKE PARTICLE (VLP) AND AMYLOID-BETA PEPTIDE | 2005 |
|
RU2415677C2 |
| DRUG FOR PREVENTION OR TREATMENT OF BRAIN ATROPHY | 2018 |
|
RU2759727C2 |
